

## Capital Increase in Genmab as a Result of Employee Warrant Exercise

### Company Announcement

**Copenhagen, Denmark; November 10, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,402 shares as a consequence of the exercise of employee warrants.**

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

750 shares at DKK 31.75,  
28,600 shares at DKK 40.41,  
3,750 shares at DKK 55.85,  
137 shares at DKK 337.40,  
500 shares at DKK 636.50,  
1,500 shares at DKK 939.50,  
701 shares at DKK 1,136.00,  
2,626 shares at DKK 1,145.00,  
2,925 shares at DKK 1,408.00, and  
5,913 shares at DKK 1,432.00.

Proceeds to the company are approximately DKK 19.55 million. The increase corresponds to approximately 0.07% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2020. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No. 377 of April 2, 2020, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 65,545,748 which is made up of 65,545,748 shares of a nominal value of DKK 1 each, corresponding to 65,545,748 votes.

### About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX<sup>®</sup> (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta<sup>®</sup> (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA<sup>®</sup> (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO<sup>™</sup> (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra<sup>®</sup> (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody<sup>®</sup> platform for generation of bispecific antibodies, the HexaBody<sup>®</sup> platform, which creates effector function enhanced antibodies, the HexElect<sup>®</sup> platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic

## Capital Increase in Genmab as a Result of Employee Warrant Exercise

potency and the DuoHexaBody<sup>®</sup> platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

### Contact:

Marisol Peron, Corporate Vice President, Communications & Investor Relations  
T: +1 609 524 0065; E: [mmp@genmab.com](mailto:mmp@genmab.com)

### For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations  
T: +45 3377 9558; E: [acn@genmab.com](mailto:acn@genmab.com)

*This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on [www.genmab.com](http://www.genmab.com) and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at [www.sec.gov](http://www.sec.gov). Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.*

*Genmab A/S and/or its subsidiaries own the following trademarks: Genmab<sup>®</sup>; the Y-shaped Genmab logo<sup>®</sup>; Genmab in combination with the Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; DuoBody<sup>®</sup>; DuoBody in combination with the DuoBody logo<sup>®</sup>; HexaBody<sup>®</sup>; HexaBody in combination with the HexaBody logo<sup>®</sup>; DuoHexaBody<sup>®</sup>; HexElect<sup>®</sup>; and UniBody<sup>®</sup>. Arzerra<sup>®</sup> and Kesimpta<sup>®</sup> are trademarks of Novartis AG or its affiliates. DARZALEX<sup>®</sup> and DARZALEX FASPRO<sup>™</sup> are trademarks of Janssen Pharmaceutica NV. TEPEZZA<sup>®</sup> is a trademark of Horizon Therapeutics plc.*